The in-depth, constantly-changing birds-eye view of disease that computational models provide is an essential next step in linking our ever-expanding clinical knowledge and data with drug development.
These structures, if not set up and managed correctly from day one, can create significant accounting, tax and compliance headaches down the road.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
AI can speed up drug discovery and decrease attrition rates in the clinic, but it is important to recognize that both are tall orders. The companies that will benefit most are those that stay grounded, set realistic expectations, and keep experienced scientists at the center of decisions that require genuine creativity and judgment.
Novellia raised $18 million in Series A funding to scale its platform, which helps patients consolidate medical records and share anonymized data with pharma companies. CEO Shashi Shankar argued that sourcing data directly from patients can create more complete healthcare datasets and improve drug research.
It's not a mystery — it’s a flaw in how knowledge is managed, where the greatest discoveries are hidden by the friction between what we already know and what we can find. Fixing it does not require more data; it requires systems capable of understanding the data.
The cell and gene therapy sector has hit incredible milestones in recent years. As the sector continues to evolve and the climate becomes increasingly crowded and volatile, leaders must remain flexible in constantly refining the pipeline.
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.
The One Big Beautiful Bill Act has drawn criticism from healthcare groups for slashing Medicaid and ACA subsidies, but it contains a few provisions that could drive progress.
Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.
Johnson & Johnson's CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it's crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.
We need to embrace principles from the tech industry and incorporate lessons learned from the pandemic to address the challenges of R&D productivity in pharma.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and some of the work his teams are doing in the COVID-19 space.
The drug industry maintains that policies like foreign reference pricing and letting Medicare negotiate prices would harm innovation. But closer examination reveals that while there is truth to that claim, it's more complex than it appears at first glance.
Red and blue states alike are ushering in new drug price legislation, building momentum while the federal government sits on its hands. What is the likely impact of these efforts on the industry?
A startup emerges from stealth mode to launch a new life sciences search engine to make the selection of reagents and equipment faster, more accurate and cost effective.
We live in a golden age of medicine. Never before have so many effective treatment options been available to so many people. And precision medicine is bringing new horizons, as well as the promise to further improve disease prevention, treatment, and ultimately find more cures. To keep moving toward personalized medicine approaches, more individuals would […]